[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.247.205. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Correction
September 13, 2006

Remissions in Maternal Depression and Child Psychopathology: A STAR*D-Child Report—Correction

JAMA. 2006;296(10):1234. doi:10.1001/jama.296.10.1234

Incomplete Financial Disclosure: In the Original Contribution entitled “Remissions in Maternal Depression and Child Psychopathology: A STAR*D-Child Report” published in the March 22/29, 2006, issue of JAMA (2006;295:1389-1398), financial disclosures were omitted. The amended disclosure statement follows: Dr Weissman reported having received grant support from Eli Lilly and GlaxoSmithKline and having served as a scientific advisor to Eli Lilly. Dr Alpert reported having received research support from Aspect Medical Systems, Eli Lilly, Forest Pharmaceuticals, and Pfizer; having received research support and honoraria from Organon Inc; and having received research support from and having served as a consultant for Pharmavite LLC and Pamlab LLC. Dr Fava reported having received research support from Abbott Laboratories, Lichtwer Pharma GmbH, Lorex Pharmaceuticals; having received honoraria from EPIX Pharmaceuticals, Bayer AG, Compellis, Cypress Pharmaceuticals, Janssen Pharmaceutica, Knoll Pharmaceutical, Lundbeck, Dov Pharmaceuticals, Biovail Pharmaceuticals, BrainCells Inc, Cypress Pharmaceuticals, Fabre-Kramer Pharmaceuticals, Grunenthal GmBH, MedAvante, Sepracor, and Somerset Pharmaceuticals; and having received both research support and honoraria from Aspect Medical Systems, Astra-Zeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Novartis, Organon, Pamlab, Pharmavite, Pfizer, Roche, Sanofi/Synthelabo, Solvay Pharmaceuticals, and Wyeth-Ayerst Laboratories. Dr Trivedi reported having provided scientific consultation for or having served on the advisory boards of Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Pharmaceuticals, Johnson & Johnson, Pfizer, Sepracor, and Wyeth-Ayerst Laboratories; having served on the speaker bureaus for Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Pharmaceuticals, and Wyeth-Ayerst Laboratories; and having received researchsupport from Bristol-Myers Squibb, Cephalon, Corcept Therapeutics, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica, National Institute of Mental Health, National Alliance for Research in Schizophrenia and Depression, Pfizer, Predix Pharmaceuticals, and Wyeth-Ayerst Laboratories. Dr Rush reported having provided scientific consultation to or served on advisory boards of Advanced Neuronetic Systems, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Health Technology Systems, Merck, Neuronetics, Ono Pharmaceuticals, Organon Pharmaceuticals, Pfizer, the Urban Institute, and Wyeth-Ayerst Laboratories; having received royalties from Guilford Press and Health Technology Systems and research and grant support from the Robert Wood Johnson Foundation, the National Institute of Mental Health, and the Stanley Foundation; having served on the speaker bureaus of Cyberonics, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, and Merck; and owning stock in Pfizer.

×